Product
FOLFOXIRI and Bevacizumab
1 clinical trial
1 indication
Indication
Colorectal CancerClinical trial
Conversion From Unresectable To Resectable Liver Metastases In Patients With Liver-Only Metastatic Colorectal Cancer Treated With FOLFOXIRI Plus Bevacizumab. The Conversion Trial.Status: Not yet recruiting, Estimated PCD: 2026-03-31